Vertex Pharmaceuticals' unchanged guidance and disappointing trial outcomes for its investigative pain relief treatment led ...

Vertex Pharmaceuticals' Seaport headquarters buildings have been refinanced for $1 billion, putting a ten-figure value on an ...

The heritage British brand has been revived by a chairman whose impressive career before watchmaking includes a three-year ...

Vertex Pharmaceuticals ( VRTX) plunged after Q2 earnings and is now down 21% over the past year. The company has historically ...

Vertex Pharmaceuticals Incorporated's stock drop is overblown. With strong CF revenue, pipeline potential, & insider ...

A federal judge ruled Hampton’s Zoning Board had ample evidence to reject the tower, but left one legal claim standing.

The RMR Group secured a $1 billion refinancing for Vertex Pharmaceuticals' Boston Seaport headquarters, a five-year, interest ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage ...

Vertex Corp. (5290.TO) Japan 1st Quarter Ended June 30 GROUP 2025 2024 Revenue Y8.70 bln Y8.24 bln Operating Profit Y1.08 bln Y781.00 mln Pretax Profit Y1.15 bln Y830.00 mln Net Profit Y658.00 mln ...

Vertex Pharmaceuticals beat Wall Street estimates for quarterly results on Monday, helped by demand for its new cystic ...

Shares of Vertex Pharmaceuticals sank 15% after the drugmaker announced a study showed its experimental pain medicine was not ...